/
IMMX
$10.49+$0.51 (+5.11%)live
Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Market cap
$710.5M
71M shares
52-week range
$1.94 – $11.61
88% from low
Sector
PHARMACEUTICAL PREPARATIONS
Exchange
NASDAQ
CS
Borrow rate
0.66%
Easy to borrow
Price (6 mo)
Loading chart…
Change+$6.82
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Cost of revenue | $0 | $0 | $0 | $0 | $0 | $0 | $364.5K |
| Gross profit | $0 | $0 | $0 | $0 | $0 | $0 | −$364.5K |
| Gross margin | — | — | — | — | — | — | — |
| R&D | $583.2K | $248.1K | $126.5K | $4.2M | $8.7M | $11.3M | $16.3M |
| Operating income | −$842.5K | −$453.9K | −$1.4M | −$8.2M | −$16.1M | −$22.7M | −$27.2M |
| EBITDA | −$841.4K | −$451.5K | −$24.2M | −$8.2M | −$15.6M | −$21.5M | −$29.0M |
| Net income | −$972.8K | −$1.1M | −$24.4M | −$8.2M | −$15.4M | −$21.6M | −$29.4M |
| Net margin | — | — | — | — | — | — | — |
| EPS (diluted) | -0.29 | -0.15 | -6.64 | -0.59 | -0.89 | -0.76 | -0.89 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $12M | $-0.69 | $-0.87–$-0.57 | 6 |
| 2027 | $38M | $-0.74 | $-1.28–$-0.09 | 5 |
| 2028 | $179M | $-0.38 | $-0.65–$-0.11 | 2 |
| 2029 | $313M | $0.28 | $0.16–$0.40 | 1 |
Forward consensus · source: Financial Modeling Prep
DCF fair valuemodel estimate
Intrinsic value
$2.66
Price
$10.49
Implied downside
-75%
Peer comparison
Immix Biopharma, Inc. Common Stock
Immix Biopharma Inc is engaged in the discovery and development of novel cell therapies for hematologic malignancies (blood cancers) and other indications. It is a clinical-stage biopharmaceutical company developing a novel class of Tissue-Specific Therapeutics TM in oncology and inflammation. Its TME Normalization Technology allows drug candidates to circulate in the bloodstream, exit through tumor blood vessels and simultaneously attack all components of the TME. Its product candidates include CAR-T NXC-201 for autoimmune diseases, and IMX-110 for treatment of soft tissue sarcoma.
www.immixbio.com- Employees
- 21
- IPO / List date
- Dec 16, 2021
- HQ
- LOS ANGELES, CA
Held by traders on TradeandTell
No one on the platform currently holds IMMX.
Super investors & insiders
Institutions holding (13F)
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2025-12-31 | 258,600 | $1.4M |
Insider activity (SEC Form 4)
Recent trades on TradeandTell
No one on the platform has traded IMMX yet.
